Skip to main
  1. Stocks
  2. Medline Inc
  3. Forecast
MDLN

Medline Inc (MDLN) Stock Forecast & Price Target

Medline Inc (MDLN) Analyst Ratings

Based on 24 analyst ratings
Buy
Strong Buy 33%
Buy 50%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Medline is attractive because its dominant U.S.-focused scale, with over 90% of revenue generated domestically, 30+ manufacturing facilities, ~45 distribution centers, and 2,000+ owned trucks, supports a resilient and highly integrated supply chain model that is hard for competitors to replicate. Its 1,300+ Prime Vendor relationships and ~$2.4B of Prime Vendor signings in 2025 create a long-duration pipeline for converting lower-margin supply-chain revenue into higher-margin Medline Brand sales, with management estimating ~$4B of current conversion opportunity that could translate into roughly $1B of incremental gross profit. Near-term demand also appears strong, as 3Q:26 revenue rose 10.4% y/y, adjusted EBITDA beat expectations even excluding an $81M tariff refund benefit, and 2027E guidance still points to high-single-digit revenue growth plus ~$80M-$90M of annualized restructuring savings.

Bears say

Medline is facing a negative setup because tariff-driven headwinds, raw-material inflation, and elevated transportation and remediation costs are compressing margins just as management expects Supply Chain Solutions margins to stay around 4.4% in 4Q after prior expectations of about 5% for FY26. Its initial FY27 framework for low-to-mid single-digit EBITDA growth already reflects a difficult cost environment, and two-thirds of the roughly $200 million increase in costs is expected in 4Q:26, raising concern around near-term earnings pressure. In addition, BBBA-related Medicaid cuts and expired exchange subsidies may reduce hospital volumes and tighten customer budgets, while competitive pressure, operational complexity, and a material debt load could further limit growth and flexibility.

Medline Inc (MDLN) has been analyzed by 24 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 50% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Medline Inc and is not a guaranteed prediction by Public.com or investment advice.

Medline Inc (MDLN) Analyst Forecast & Price Prediction

Get the latest Medline Inc (MDLN) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Medline Inc (MDLN)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Medline Inc (MDLN) Forecast

Analysts have given Medline Inc (MDLN) a Buy based on their latest research and market trends.

According to 24 analysts, Medline Inc (MDLN) has a Buy consensus rating as of Nov 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $46.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $46.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Medline Inc (MDLN)


Medline Inc (MDLN) Analyst Forecast & Price Prediction

Get the latest Medline Inc (MDLN) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Medline Inc (MDLN)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover MDLN stock data and trends